Chip stocks fall with Nvidia after data center rev disappointment
Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics Inc. (NASDAQ:CYTK), has sold shares in the company valued at $4,500, according to a recent SEC filing. The transaction, dated March 14, involved the sale of 100 shares at a price of $45.00 each. The stock currently trades at $44.36, with the company commanding a market capitalization of $5.2 billion. According to InvestingPro analysis, the company’s shares are currently trading near their Fair Value.
In addition to this sale, Callos also acquired 100 shares through the exercise of stock options, priced at $23.26 per share, bringing the total value of this acquisition to $2,326. Following these transactions, Callos holds 37,663 shares directly. The company maintains strong financial flexibility, with liquid assets exceeding short-term obligations and operating with moderate debt levels.
These moves are part of Callos’s ongoing management of his equity position in the company, which is focused on developing muscle biology therapies. While the company has delivered strong returns over the past five years, InvestingPro subscribers can access 8 additional key insights about CYTK’s financial health and growth prospects through the comprehensive Pro Research Report, available exclusively on the platform.
In other recent news, Cytokinetics reported its fourth-quarter 2024 earnings, revealing a slight miss in earnings per share (EPS) with a recorded EPS of -$1.26 against an analyst forecast of -$1.22. Despite this, the company demonstrated strong revenue growth, reaching $16.9 million, a significant increase from the previous year’s $1.7 million for the same quarter. Additionally, Morgan Stanley (NYSE:MS) upgraded Cytokinetics to an Overweight rating with a $67 price target, citing anticipated developments such as the release of MAPLE-HCM study data and the potential approval of aficamten for obstructive hypertrophic cardiomyopathy (HCM).
Cytokinetics is preparing for the expected U.S. commercial launch of aficamten, with a Prescription Drug User Fee Act (PDUFA) date set for September 26, 2025. The company has submitted its 120-day safety update to the FDA and anticipates a mid-cycle meeting with the agency in March. Citi analysts have maintained a Buy rating on Cytokinetics, setting a price target of $86, and noted the FDA’s decision not to hold an advisory committee meeting for aficamten’s review as a positive step toward potential approval.
Cytokinetics has also provided financial guidance for 2025, projecting GAAP operating expenses between $670 million and $710 million. The company holds a robust cash position with $1.2 billion in cash and investments, which supports its ongoing clinical trials and commercial preparations. These recent developments highlight significant milestones for Cytokinetics, as the company continues to advance its product pipeline and engage with regulatory authorities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.